

**iTOC7**  
CONFERENCE

7<sup>TH</sup> IMMUNOTHERAPY  
OF CANCER CONFERENCE

# THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY CONFERENCE IN EUROPE

7<sup>th</sup> ImmunoTherapy of Cancer Conference  
April 2 – 4, 2020 • Munich, Germany



## SCIENTIFIC PROGRAM

[www.itoc-conference.eu](http://www.itoc-conference.eu)



# ITOC7 COMMITTEES

## ITOC7 Conference Presidents


- Mario Sznol (Yale School of Medicine, New Haven, CT, United States)
- Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

## ITOC7 Chairmen of the Scientific Committee

- Volkmar Nuessler (TzM, Munich, Germany)
- Paolo Ascierto (Istituto Nazionale Tumori, Italy)

## ITOC7 Scientific Committee

- Michael Bergmann (Medical University Vienna, Austria)
- Christian Blank (NKI, Netherlands)
- Lisa Butterfield (Parker Institute for Cancer Immunotherapy, United States)
- Tanja de Gruijl (Cancer Center Amsterdam, Amsterdam, The Netherlands)
- Samir N. Khleif (Georgetown University Medical Center, United States)
- Sebastian Kobold (Ludwig-Maximilians-Universität, Germany)
- Zihai Li (Ohio State University, Columbus, OH, USA)
- Pedro J. Romero (University of Lausanne, Switzerland)
- José Saro (Avacta Life Sciences, United Kingdom)
- Barbara Seliger (Martin Luther University Halle-Wittenberg, Germany)
- Wenru Song (Kira Pharmaceuticals, United States)
- Eric Tartour (Hôpital Européen Georges-Pompidou, France)
- Giorgio Trinchieri (Center for Cancer Research/NCI/NIH, USA)
- Lei Zheng (Johns Hopkins University, Baltimore, MD)
- Christoph Zielinski (Medical University of Vienna, Austria)






# THURSDAY, APRIL 2, 2020

09.00	Registration Opens
11.00 – 11.10	<b>Welcome Address</b> Michael von Bergwelt
11.10 – 13.30	<b>Plenary Symposium 1: Emerging Concepts / New Agents</b> Chair: Mario Sznol, Christoph Zielinski
11.10 - 11.30	Myeloid immune checkpoint inhibition Timo K. van den Berg, Amsterdam, The Netherlands
11.30 - 11.50	Potential of ADAR Pathway in immunotherapy Jeffrey Ishizuka, Boston, MA, USA
11.50 - 12.10	The Stimulator of Interferon Genes (STING) pathway. Emerging clinical data Reinhard Dummer, Zurich, Switzerland
12.10 - 12.30	Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy Christian Blank, Amsterdam, The Netherlands
12.30 - 12.50	CXCR3 required for anti-PD-1 efficacy Melvyn Chow, Boston, MA, USA
12.50 - 13.10	IL-15 for cancer therapy Mark Rubinstein, Charleston, SC, USA
13.10 - 13.30	T cell bispecific antibodies (4-1BB and tumor antigen) Pablo Umana, Zurich, Switzerland
13.30 – 14.30	Lunch
14.30 – 16.10	<b>Plenary Symposium 2: Microbiome and immunotherapy</b> Chair: Volkmar Nüssler, Giorgio Trinchieri
14.30 – 14.50	Microbiome and Immunotherapy in Cancer Giorgio Trinchieri, Bethesda, MD, USA
14.50 - 15.10	Computational metagenomics for uncovering the unexplored microbiome diversity Nicola Segata, Trento, Italy
15.10 - 15.30	Microbiome modulation for cancer therapy Hendrik Poeck, Munich, Germany
15.30 - 15.50	Microbiome and epithelial cell stress in colon cancer Dirk Haller, Munich, Germany
15.50 - 16.10	Microbiome modulation in HSC transplantation Marcel van den Brink, New York, NY, USA
16.10 – 16.40	Coffee Break



# THURSDAY, APRIL 2, 2020

16.40 – 19.10	Plenary Symposium 3: Tumor microenvironment Chair: Paolo Ascierto, Eric Tartour
16.40 - 17.00	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment Tom Gajewski, Chicago, IL, USA
17.00 - 17.20	Immunoscore as possible predictive marker of response to treatments Franck Pages, Paris, France
17.20 - 17.40	Tumor intrinsic vs tumor extrinsic immune suppression Kai Wucherpennig, Boston, MA, USA
17.40 - 18.00	Arming oncolytic viruses for DC activation and recruitment in melanoma T.D. de Gruijl, Amsterdam, The Netherlands
18.00 - 18.20	Dissecting the interplay between tumor cells and the immune system in melanoma progression and response to therapy Marisol Soengas, Madrid, Spain
18.20 - 18.40	Pancreatic Cancer Tumor Microenvironment Lei Zheng, Baltimore, MD, USA
18.40 - 18.55	Speaker 6 – from submitted abstracts
18.55 - 19.10	Speaker 7 – from submitted abstracts
19.10 – 22.00	Welcome Reception and Poster Viewing (at the venue)





# FRIDAY, APRIL 3, 2020

- 08.30 – 09.30      Plenary Symposium 4: Vaccine Therapy  
Chair: Barbara Seliger, Lei Zheng
- 08.30 - 08.50      Mucosal vaccinations for cancer treatment  
Georg Stary, Vienna, Austria
- 08.50 - 09.10      Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma  
Lisa Butterfield, San Francisco, CA, USA
- 09.10 - 09.30      Vaccine therapy in reversing anti -PD1 resistance  
Samir Khleif, Washington, DC, USA
- 09.30 – 10.30      Pro & Contra Session: Blinatumomab vs anti-CD19 CAR T cells: which treatment should be preferred and when? Can we treat with either regimen after relapse on the other?  
Chair: Dominik Wolf, Wolfgang Herr
- 09.30 – 10.00      Pro Bite  
Max Topp, Würzburg, Germany
- 10.00 – 10.30      Pro CAR  
Marion Subklewe, Munich, Germany
- 10.30 – 11.00      Coffee Break
- 11.00 – 12.30      Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)  
Chair: Lisa Butterfield, José Saro
- 11.00 – 11.20      High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy  
Pier Federico Gherardini, San Francisco, CA, USA
- 11.20 – 11.40      FcR macrophage and hyperprogressor  
Giuseppe Lo Russo, Milano, Italy
- 11.40 - 12.00      Novel splice isoforms, target for immunotherapy  
Jacques Banchereau, Bar Harbor, ME, USA
- 12.00 – 12.15      Speaker 4 – from submitted abstracts
- 12.15 – 12.30      Speaker 5 – from submitted abstracts
- 12.30 – 14.00      Lunch
- 14.00 – 15.00      Satellite Symposium
- 15.00 – 15.45      Lifetime Achievement Award  
Chair: Michael von Bergwelt
- The 34th anniversary of interleukin 6; a major player in inflammation, autoimmunity and cancer  
Toshio Hirano, Chiba, Japan
- 15.45 – 16.15      Coffee Break



# FRIDAY, APRIL 3, 2020

16.15 – 17.10	Plenary Symposium 6: "Lost in Translation" Chair: Alfred Zippelius, Philipp Beckhove
16.15 – 16.35	Ups and downs of IDO inhibition in cancer treatment George Prendergast, Philadelphia, PA, USA
16.35 – 16.55	Why adoptive T cell therapies fail solid tumors? Sebastian Kobold, Munich, Germany
16.55 – 17.10	Speaker 3 – from submitted abstracts
17.10 – 18.10	Plenary Session 7: Young Researcher Session Chair: Sebastian Kobold, Zihai Li
17.10 – 17.25	Speaker 1 - from submitted abstracts
17.25 – 17.40	Speaker 2 - from submitted abstracts
17.40 – 17.55	Speaker 3 - from submitted abstracts
17.55 - 18.10	Speaker 4 - from submitted abstracts
19.30	ITOC7 Conference Dinner




- 08.00 – 09.05      **Plenary Symposium 8: Cell Therapy in Solid Tumors**  
Chair: Christian Blank, Pedro Romero
- 08.00 – 08.20      Challenges of T-cell therapy in solid tumors  
Cassian Yee, Houston, TX, USA
- 08.20 – 08.35      Novel CAR formats for solid tumors  
Hidde Ploegh, Boston, MA, USA
- 08.35 – 08.50      Novel strategies to enable T cell therapy of cancer  
Per Thor Straten, Herlev, Denmark
- 08.50 – 09.05      CAR T cell therapy in non hematological pediatric cancer  
Franco Locatelli, Rome, Italy
- 09.05 – 10.20      **Plenary Symposium 9: Cell Therapy in Haematologic Diseases**  
Chair: Florian Bassermann, Hinrich Abken
- 09.05 – 09.25      Cell therapy of hematological malignancies  
Chiara Bonini, Milan, Italy
- 09.25 – 09.45      New targets and technologies for CAR-T  
Michael Hudecek, Würzburg, Germany
- 09.45 – 10.05      Genome edited T cells for leukaemia  
Waseem Quasim, London, United Kingdom
- 10.05 - 10.20      Speaker 4 – from submitted abstracts
- 10.20 – 10.50      Coffee Break
- 10.50 – 13.15      **Plenary Symposium 10: Combination Therapy**  
Chair: Michael Bergmann, Samir Khleif
- 10.50 – 11.10      Combination of innate immune stimulation with immune check point blockade for cancer therapy  
Simon Heidegger, Munich, Germany
- 11.10 - 11.30      Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer  
Marleen Kok, Amsterdam, The Netherlands
- 11.30 - 11.50      Targeting the tumour microenvironment through co-neutralization of IL-1beta and PD-1 to attenuate MRD  
Ron-Nathan Apte, Beer Sheva, Israel
- 11.50 - 12.10      Targeting immunosuppressive adenosine pathway in cancer  
Rakesh Kumar, Gaithersburg, MD, USA
- 12.10 - 12.30      GARP-directed cancer immunotherapy: mechanisms and opportunities  
Zihai Li, Columbus, OH, USA






# SATURDAY, APRIL 4, 2020

10.50 – 13.15	Plenary Symposium 10: Combination Therapy (cont.)
12.30 – 12.45	Speaker 6 – from submitted abstracts
12.45 - 13.00	Speaker 7 – from submitted abstracts
13.00 - 13.15	Speaker 8 – from submitted abstracts
13.15 - 13.30	Best Poster Awards & Closing Remarks Chair: Volkmar Nüssler
13.30 - 14.30	Lunch





THE LEADING INTERNATIONAL CANCER IMMUNOTHERAPY  
CONFERENCE IN EUROPE

**CONFERENCE MATTERS**

**WMA GmbH**  
Catherine Tomek  
itoc@medacad.org  
Tel.: +43 1 405 13 83 18

[www.itoc-conference.eu](http://www.itoc-conference.eu)